advertisement
Abstract #104789 Published in IGR 23-2
Inhibitory Efficacy of Thiosemicarbazones for Carbonic Anhydrase II (Bovine and Human) as a Target of Calcification and Tumorigenicity
Khan M; Halim SA; Shafiq Z; Islam M; Shehzad MT; Ibrar A; Khan FA; Marraiki N; Uddin J; Khan A; Al-Harrasi ACurrent Pharmaceutical Design 2022; 0:
BACKGROUND: Carbonic anhydrase II (CA-II) is associated with calcification, tumorigenicity, epilepsy, osteoporosis, and several other physiological or pathological processes. CA-II inhibitors can be used to reduce the intraocular pressure usually associated with glaucoma. OBJECTIVE: In search of potent CA-II inhibitors, a series of thiosemicarbazone derivatives (3a-u) was synthesized. METHODS: This series was evaluated against bovine and human carbonic anhydrase II (bCA-II and hCA-II) and their docking studies were carried out. RESULTS: In the preliminary screening, most of the compounds exhibited significant inhibition of bCA-II and hCA-II. The predictive structure-activity relationship suggested that the thiosemicarbazide moiety play a key role in the inhibition of enzyme activity and substitution at R position and has a remarkable contribution to the overall activity. The kinetics studies of the most active inhibitors of bCA-II (3d, 3e, 3l, 3f, and 3p) and hCA-II (3g) were performed against bCA-II and hCA-II, respectively to investigate their mode of inhibition and dissociation constants (Ki). CONCLUSION: Subsequently, 3e, 3f, 3l and 3p were identified as competitive inhibitors of bCA-II with Ki values of 5.02-14.70 µM, while 3d as a noncompetitive inhibitor of bCA-II (Ki = 2.5±0.015 µM), however, 3g demonstrated competitive inhibition of hCA-II with Ki value of 5.95±0.002 µM. The selectivity index reflects that the compound 3g is more selective for hCA-II. The binding modes of these compounds with bCA-II and hCA-II were investigated by structure-based molecular docking, and the docking results are in complete agreement with the experimental findings.
Full article
